← Back
No items found.
April 14, 2021

A stronger team

We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.

Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.

For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.

With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047

April 14, 2021

A stronger team

We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.

Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.

For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.

With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047

Author:

Per von Mentzer

Author:

Per von Mentzer

CTC AWARDED AS CRO

It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC)

Read more →

CANADA PATENT GRANT

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in Canada. Previously patent has been granted in the USA, the EU, Japan, Australia and China. Canada was the last major country remaining for PN6047.

Read more →

MEET OUR CMO

PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer. Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies.

Read more →

In memory of Hans G.

Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.

Read more →
Latest
breaking
news

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden

Map